FFA
PSTX

Farther Finance Advisors’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Farther Finance Advisors’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-80
Closed -$768 – 4463
2024
Q4 		$768 Hold
80
– – ﹤0.01% 3331
2024
Q3 		$229 Sell
80
-93
-54% -$288 ﹤0.01% 3625
2024
Q2 		$521 Buy
173
+71
+70% +$194 ﹤0.01% 3277
2024
Q1 		$316 Hold
102
– – ﹤0.01% 3155
2023
Q4 		$343 Buy
+102
New +$263 ﹤0.01% 3099

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Farther Finance Advisors's PSTX Position: Q1 2025 in Review

Farther Finance Advisors sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 80 shares — an estimated $768 sold.

Farther Finance Advisors first reported a position in PSTX in Q4 2023 and held it in 5 quarters. The position peaked at $768 in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Farther Finance Advisors reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Farther Finance Advisors sold 80 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $768.
  • Farther Finance Advisors first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2023 and held it in 5 quarters.
  • Farther Finance Advisors's Poseida Therapeutics, Inc. Common Stock position peaked at $768 in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Farther Finance Advisors's 13F filing for Q1 2025, filed 14 Apr 2025.